Myriad Genetics to stop developing Alzheimer’s drug (Reuters)
Reuters - Myriad Genetics Inc said it will stop
developing its drug for Alzheimer's disease after a late-stage
trial of the drug, Flurizan, failed to meet primary goals.
-->